Cargando…

Efficacy and safety of (177)Lutetium-prostate-specific membrane antigen therapy in metastatic castration-resistant prostate cancer patients: First experience in West Asia – A prospective study

Prostate-specific membrane antigen (PSMA) is a transmembrane protein that is highly expressed on the surface of prostate cancer (PC) cells, making it an excellent radiotracer for both therapeutic and diagnostic purposes. In this prospective study, we investigated the efficacy and toxicity of (177)Lu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aghdam, Ramin Akbarian, Amoui, Mahasti, Ghodsirad, Mohammadali, Khoshbakht, Sepide, Mofid, Bahram, Kaghazchi, Fateme, Tavakoli, Mehrdad, Pirayesh, Elahe, Ahmadzadehfar, Hojjat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714159/ https://www.ncbi.nlm.nih.gov/pubmed/31516369 http://dx.doi.org/10.4103/wjnm.WJNM_66_18

Ejemplares similares

Metachronous Brain Tumor in 177Lu-PSMA Scan in a Patient with Metastatic Castration Resistant Prostate Cancer Mimicking Disease Progression
por: Pirayesh, Elahe, et al.
Publicado: (2023)

Comparison of Accuracy in Calculation of Absorbed Dose to the Kidneys Following Radioligand Therapy with (177)Lu-DKFZ-PSMA-617 by Two Different Background Correction Methods
por: Mahmoudi, Elahe, et al.
Publicado: (2022)

Adoption of Lutetium-(177) PSMA radioligand therapy for metastatic castration resistant prostate cancer: a total population analysis in Germany from 2016 to 2020
por: Flegar, Luka, et al.
Publicado: (2023)

Potential application of lutetium-177-labeled prostate-specific membrane antigen-617 radioligand therapy for metastatic castration-resistant prostate cancer in a limited resource environment: Initial clinical experience after 2 years
por: Assadi, Majid, et al.
Publicado: (2020)

Uptake Difference by Somatostatin Receptors in a Patient with Neuroendocrine Tumor: 99mTc-Octreotide Uptake in the Lung without Uptake in Liver Lesions
por: Pirayesh, Elahe, et al.
Publicado: (2015)

Lutetium-177 prostate-specific membrane antigen-617 theranostics: New therapeutic hope in metastatic castrate-resistant prostate cancer?
por: Ranjan, Satish Kumar
Publicado: (2020)

Lutetium-177 Prostate-Specific Membrane Antigen-617 Treatment in Metastatic Castration-Resistant Prostate Adenocarcinoma: Results of Single-Center Experience
por: Maman, Adem
Publicado: (2023)

Renal outcomes of radioligand therapy: experience of (177)lutetium—prostate-specific membrane antigen ligand therapy in metastatic castrate-resistant prostate cancer
por: Gallyamov, Marat, et al.
Publicado: (2019)

Review of Lutetium-177-labeled Anti-prostate-specific Membrane Antigen Monoclonal Antibody J591 for the Treatment of Metastatic Castration-resistant Prostate Cancer
por: Niaz, Muhammad O, et al.
Publicado: (2020)

Clinical Variables Associated with PSA Response to Lutetium-177-PSMA ([177Lu]-PSMA-617) Radionuclide Treatment in Men with Metastatic Castration-Resistant Prostate Cancer
por: Gadot, Moran, et al.
Publicado: (2020)

Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
por: Awang, Zool Hilmi, et al.
Publicado: (2018)

(177)Lu-DOTATATE and (177)Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment
por: Assadi, Majid, et al.
Publicado: (2019)

Therapeutic response and side effects of repeated radioligand therapy with (177)Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer
por: Ahmadzadehfar, Hojjat, et al.
Publicado: (2016)

First communication on the efficacy of combined (177)Lutetium-PSMA with immunotherapy outside prostate cancer
por: Digklia, Antonia, et al.
Publicado: (2022)

Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [(177)Lu]Lu-PSMA-617 radioligand therapy
por: Ahmadzadehfar, Hojjat, et al.
Publicado: (2017)

Efficacy and Haematologic Toxicity of Palliative Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen in Heavily Pre-Treated Patients
por: Kesavan, Murali, et al.
Publicado: (2021)

Lutetium-177-Labeled Prostate-Specific Membrane Antigen-617 for Molecular Imaging and Targeted Radioligand Therapy of Prostate Cancer
por: Ritawidya, Rien, et al.
Publicado: (2023)

Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study
por: Ahmadzadehfar, Hojjat, et al.
Publicado: (2015)

Treatment of Advanced Metastatic Prostate Cancer Using Molecular-Targeted Therapy: Radioligand Lutetium-177 Prostate-Specific Membrane Antigen
por: Rathore, Rajni, et al.
Publicado: (2023)

Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy
por: Ruigrok, Eline A. M., et al.
Publicado: (2020)

Lutetium-177 Labelled PSMA Targeted Therapy in Advanced Prostate Cancer: Current Status and Future Perspectives
por: Seitzer, Konstantin Egon, et al.
Publicado: (2021)

A Review of 177Lutetium-PSMA and 225Actinium-PSMA as Emerging Theranostic Agents in Prostate Cancer
por: Alam, Mohammad R, et al.
Publicado: (2022)

Challenges and future options for the production of lutetium-177
por: Vogel, W. V., et al.
Publicado: (2021)

Lutetium Lu-177 Dotatate Flare Reaction
por: Salner, Andrew L., et al.
Publicado: (2020)

Complete Radiologic Response in Metastatic Castration-Resistant Prostate Cancer Treated with Cabazitaxel
por: Mofid, Bahram, et al.
Publicado: (2015)

Inter-comparison of quantitative imaging of lutetium-177 ((177)Lu) in European hospitals
por: Wevrett, Jill, et al.
Publicado: (2018)

Circulating Tumour DNA Biomarkers Associated with Outcomes in Metastatic Prostate Cancer Treated with Lutetium-177-PSMA-617
por: Crumbaker, Megan, et al.
Publicado: (2023)

Lutetium-177-PSMA-617: A Vision of the Future
por: Chandran, Elias, et al.
Publicado: (2022)

Lutetium Lu 177 Vipivotide Tetraxetan: First Approval
por: Keam, Susan J.
Publicado: (2022)

Safety and Therapeutic Optimization of Lutetium-177 Based Radiopharmaceuticals
por: Ladrière, Typhanie, et al.
Publicado: (2023)

Personalized [177Lu]Lutetium-PSMA Therapy for Patients with Pre-Treated Castration-Resistant Prostate Cancer: A Single Institution Experience from a Comprehensive Cancer Centre
por: Thaiss, Wolfgang, et al.
Publicado: (2023)

Technical Considerations of Phosphorous-32 Bremsstrahlung SPECT Imaging after Radioembolization of Hepatic Tumors: A Clinical Assessment with a Review of Imaging Parameters
por: Pirayesh, Elahe, et al.
Publicado: (2014)

Combined biology-guided radiotherapy and Lutetium PSMA theranostics treatment in metastatic castrate-resistant prostate cancer
por: Gaudreault, Mathieu, et al.
Publicado: (2023)

AR and PI3K Genomic Profiling of Cell-free DNA Can Identify Poor Responders to Lutetium-177-PSMA Among Patients with Metastatic Castration-resistant Prostate Cancer
por: Vanwelkenhuyzen, Jan, et al.
Publicado: (2023)

Somatostatin-receptor avidity of pancreatic neuroendocrine tumor thrombus in porto-caval venous systems on (99m)Tc-Octreotide and posttherapeutic (177)Lu-DOTA-TATE scans
por: Amoui, Mahasti, et al.
Publicado: (2021)

(177)Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
por: Sanli, Yasemin, et al.
Publicado: (2021)

Lutetium-177 DOTATATE Production with an Automated Radiopharmaceutical Synthesis System
por: Aslani, Alireza, et al.
Publicado: (2015)

Neuroendocrine Tumor Therapy with Lutetium-177: A Literature Review
por: Maqsood, Muhammad Haisum, et al.
Publicado: (2019)

Lutetium-177 Dotatate-Induced Hemolytic Anemia and Myelodysplastic Syndrome
por: Alkassis, Samer, et al.
Publicado: (2022)

Lutetium (177) PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy
por: Emmett, Louise, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_esaq2jb5qmmkvt24q9543sh34o